Rodrigo E Mendes Selected Research

Linezolid (Zyvox)

1/2022	Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
1/2017	Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strain.
4/2014	Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.
8/2013	Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents.
11/2012	Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.
4/2012	Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
12/2010	Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.
2/2010	Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
4/2009	TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
6/2008	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodrigo E Mendes Research Topics

Disease

65	Infections 07/2022 - 04/2008
11	Pneumonia (Pneumonitis) 06/2021 - 11/2010
6	Sepsis (Septicemia) 01/2022 - 12/2009
6	Urinary Tract Infections (Urinary Tract Infection) 12/2020 - 12/2015
5	Healthcare-Associated Pneumonia 07/2022 - 11/2010
5	Endocarditis 01/2021 - 09/2009
5	Bacteremia 01/2020 - 09/2009
5	Bacterial Pneumonia 12/2018 - 09/2012
4	Ventilator-Associated Pneumonia 07/2022 - 07/2015
3	Intraabdominal Infections 01/2019 - 12/2015
3	Osteomyelitis 04/2018 - 01/2016
2	Soft Tissue Infections 12/2021 - 02/2015
2	Cystic Fibrosis (Mucoviscidosis) 06/2021 - 07/2016
2	Respiratory Tract Infections (Respiratory Tract Infection) 05/2017 - 01/2016
1	Communicable Diseases (Infectious Diseases) 01/2020
1	Bacterial Endocarditis 01/2019
1	Pyelonephritis 08/2018
1	Neoplasms (Cancer) 01/2018
1	Empyema 01/2017
1	Cross Infection (Nosocomial Infection) 11/2016
1	Cardiomyopathies (Cardiomyopathy) 08/2013
1	Ototoxicity 09/2009

Drug/Important Bio-Agent (IBA)

14	Ceftaroline FDA Link 01/2021 - 11/2010
12	oritavancinIBA 01/2022 - 04/2012
10	Linezolid (Zyvox)FDA Link 01/2022 - 06/2008
10	dalbavancinIBA 06/2021 - 05/2015
8	telavancin FDA Link 01/2020 - 08/2010
7	ceftazidime drug combination avibactamIBA 12/2021 - 07/2015
6	Cephalosporins (Cephalosporin Antibiotics)IBA 07/2022 - 09/2012
5	ceftobiproleIBA 07/2022 - 01/2016
5	Carbapenems (Carbapenem Antibiotics)IBA 03/2022 - 04/2009
5	tedizolidIBA 06/2021 - 01/2019
4	avibactamIBA 03/2022 - 09/2012
4	Tazobactam FDA LinkGeneric 03/2022 - 06/2013
4	tazobactam drug combination ceftolozaneIBA 12/2021 - 09/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 07/2016
4	Vancomycin FDA LinkGeneric 11/2012 - 02/2010
3	Aztreonam FDA LinkGeneric 03/2022 - 10/2021
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2013
3	CoagulaseIBA 07/2019 - 12/2009
2	Daptomycin FDA Link 01/2022 - 01/2020
2	ceftobiprole medocarilIBA 01/2020 - 07/2019
2	ProdrugsIBA 01/2020 - 07/2019
2	plazomicinIBA 05/2019 - 01/2018
2	LactamsIBA 01/2017 - 12/2015
2	beta-Lactamases (beta-Lactamase)IBA 04/2014 - 09/2008
2	ceftolozaneIBA 12/2013 - 06/2013
2	Tigecycline (Tygacil)FDA Link 04/2012 - 04/2008
1	Cefepime (Maxipime)FDA LinkGeneric 03/2022
1	Ceftibuten (Cedax)FDA Link 01/2022
1	Imipenem FDA Link 12/2021
1	relebactamIBA 12/2021
1	meropenem and vaborbactamIBA 12/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 12/2020
1	Sulfamethoxazole FDA LinkGeneric 12/2020
1	Trimethoprim (Proloprim)FDA LinkGeneric 12/2020
1	FluoroquinolonesIBA 12/2020
1	SPR741IBA 04/2020
1	Ceftazidime (Fortum)FDA LinkGeneric 01/2019
1	tebipenemIBA 01/2019
1	Doripenem FDA Link 08/2018
1	Metronidazole (Metric)FDA LinkGeneric 01/2017
1	carbapenemaseIBA 01/2017
1	Meropenem (Merrem)FDA LinkGeneric 01/2017
1	MacrolidesIBA 01/2017
1	Piperacillin FDA LinkGeneric 04/2016
1	lefamulinIBA 01/2016
1	LipoglycopeptidesIBA 01/2016
1	Anti-Infective Agents (Microbicides)IBA 12/2014
1	EnzymesIBA 09/2012
1	quinupristin-dalfopristin (Synercid)FDA Link 04/2012
1	AminoglycosidesIBA 04/2012
1	TeicoplaninIBA 09/2011
1	Methicillin (Metin)FDA Link 09/2011
1	Fusidic Acid (Fucithalmic)IBA 06/2011
1	Oxazolidinones (2 Oxazolidone)IBA 12/2010
1	Fluconazole (Zonal)FDA LinkGeneric 09/2009
1	Tobramycin (Nebcin)FDA LinkGeneric 09/2009
1	Serine (L-Serine)FDA Link 09/2008

Therapy/Procedure

4	Therapeutics 01/2019 - 09/2009
2	Mechanical Ventilators (Ventilator) 11/2016 - 11/2010
1	Lasers (Laser) 03/2016
1	Drug Therapy (Chemotherapy) 04/2014
1	Heart-Assist Devices 08/2013